This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Queen's University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias
Blood advances · 2026
Latest funding
- $1,197,227
RATIONAL (Role of Antibiotic Therapy or Immunoglobulin On iNfection in hAematoLogy) Platform Trial: An RCT of continuing immunoglobulin therapy, or stopping with or without prophylactic antibiotics, on infection rate in patients with acquired hypogammaglobulinemia secondary to haematological malignancies
CIHR · 2024 · Co-investigator
- $3,056,172
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
CIHR · 2023 · Co-investigator
- $3,056,176
The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
CIHR · 2023 · Co-investigator
1 publications.
Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias
Bhella S, Agbayani G, Hueniken K, Vijenthira A, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Hosseini-Moghaddam SM
RATIONAL (Role of Antibiotic Therapy or Immunoglobulin On iNfection in hAematoLogy) Platform Trial: An RCT of continuing immunoglobulin therapy, or stopping with or without prophylactic antibiotics, on infection rate in patients with acquired hypogammaglobulinemia secondary to haematological malignancies
Principal investigators: Callum, Jeannie L; Reiman, Tony
Keywords: Adaptive Platform Trial; Antibiotic Therapy; Hematologic Malignancies; Hypogammaglobulinemia; Immunoglobulin; Infections
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
Principal investigators: Hay, Annette; Mian, Hira
Keywords: De-Escalation; Economic Analysis; Multiple Myeloma; Quality Of Life; Randomized Phase Iii Trial
The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
Principal investigators: Hay, Annette; Bramson, Jonathan L; Delisle, Jean-Sébastien; Leblanc, Richard; Quizi, Jennifer L
Keywords: Biomanufacturing; Cancer; Cell Therapy; Clinical Trial; First-In-Human; Immunotherapy; Multiple Myeloma; Relapsed And Refractory; Synthetic Androgen Receptor
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Principal investigators: Hay, Annette; Cheung, Matthew C
Keywords: Chronic Lymphocytic Leukemia; Economics; Non-Inferiority; Quality Of Life; Randomized Controlled Trial; Toxicity
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Principal investigators: Hay, Annette; Cheung, Matthew C
Keywords: Chronic Lymphocytic Leukemia; De-Escalation; Non-Inferiority; Randomized Controlled Trial; Toxicity
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Department of Medicine
- Medicine
- Oncology
- Infectious Diseases
- Department of Surgery
- Surgery
- Pediatrics
- Other
Co-authors at Queen's University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Deepali Kumar
Infectious Diseases
1 shared papers, latest 2026
James Brooks
Faculty
1 shared papers, latest 2026
Natasha Kekre
Surgery
1 shared papers, latest 2026
Natasha Kekre
Department of Medicine
1 shared papers, latest 2026
Christopher Bredeson
Faculty
1 shared papers, latest 2026
Tara Baetz
Faculty
1 shared papers, latest 2026
Natasha Kekre
Medicine
1 shared papers, latest 2026
Shelly Bolotin
Epidemiology Division
1 shared papers, latest 2026
Arleigh McCurdy
Department of Medicine
1 shared papers, latest 2026
David Allan
Department of Medicine
1 shared papers, latest 2026
Stephen Betschel
Department of Medicine
1 shared papers, latest 2026
Michael Chu
Department of Surgery
1 shared papers, latest 2026
Amaris Karin Balitsky
Oncology
1 shared papers, latest 2026
Michael Sebag
Medicine
1 shared papers, latest 2026
Curtis Cooper
Department of Medicine
1 shared papers, latest 2026
Shelly Bolotin
Pediatrics
1 shared papers, latest 2026
Donna Reece
Faculty
1 shared papers, latest 2026
Shelly Bolotin
Faculty
1 shared papers, latest 2026
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.